FDA Grants Fast-Track Status to New Treatment for Wet AMD

The U.S. Food and Drug Administration (FDA) recently granted Ohr Pharmaceutical’s Squalamine, a new treatment for wet-AMD, with fast track status and a Special Protocol Assessment (SPA) to speed up progress towards a Phase III clinical trial of the drug.


http://ping.fm/wIc9W